Pulse Biosciences to Present at Gilmartin Group Emerging Growth Showcase
September 07 2023 - 4:05PM
Business Wire
Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company
primarily focused on leveraging its novel and proprietary
Nanosecond Pulsed Field Ablation (nsPFA) technology for the
treatment of atrial fibrillation, today announced plans to
participate at the upcoming Gilmartin Group Emerging Growth
Showcase, taking place virtually. Members of management are
scheduled to present on Thursday, September 21, 2023 at 10:30am
PT.
A live and archived webcast of the presentation will be
available following the event on the “Investors” section of the
company’s website at http://investors.pulsebiosciences.com/.
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company
committed to health innovation that has the potential to improve
the quality of life for patients. The Company’s proprietary
Nanosecond Pulsed Field Ablation (nsPFA) technology delivers
nanosecond pulses of electrical energy to non-thermally clear cells
while sparing adjacent noncellular tissue. The Company is actively
pursuing the development of its nsPFA technology for use in the
treatment of atrial fibrillation and in a select few other markets
where nsPFA could have a profound positive impact on healthcare for
both patients and providers.
Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA
and the stylized logos are among the trademarks and/or registered
trademarks of Pulse Biosciences, Inc. in the United States and
other countries.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230907184712/en/
Investor Contacts: Pulse Biosciences Kevin Danahy,
President and CEO 510.241.1077 IR@pulsebiosciences.com
or
Gilmartin Group Philip Trip Taylor 415.937.5406
philip@gilmartinir.com
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Jul 2024 to Aug 2024
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Aug 2023 to Aug 2024